DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Gilead Sciences (NASDAQ: GILD)

103.70 -1.51 (-1.44%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $103.70 -1.44%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $104.64
Previous Close $105.21
Daily Range $103.60 - $105.68
52-Week Range $71.63 - $116.83
Market Cap $154.4B
P/E Ratio 14.31
Dividend (Yield) $0.00 (0.0%)
Volume 9,728,563
Average Daily Volume 11,001,081
Current FY EPS $10.18

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary Rss Feed

Can You Guess Which State Won't Pay for Hepatitis C Drugs?

One state decided to take a hard line stance against Gilead's pricey hep C drugs last year. And this decision may end up turning into a huge windfall for AbbVie's rival therapy. Here's why.

3 'Safe' Biotech Picks

Why Healthcare is the Best Sector For Your Money

Our experts weigh in.

I Called It: What's The Take Home Message?

Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog

AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog

Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More

AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board

Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

See More GILD News...

GILD's Top Competitors

GILD $103.70 (-1.44%)
Current stock: GILD
CELG $118.71 (2.26%)
Current stock: CELG
BIIB $401.71 (-6.64%)
Current stock: BIIB
$0.00 (0.00%)
Current stock: